Clinical Trial

Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study. The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants. The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.
Trial Details
NCT Number NCT07511010
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions T2DM (Type 2 Diabetes Mellitus)
Enrollment 28 participants
Start Date 2026-10-08
Primary Completion 2026-10-26 (estimated)
Study Completion 2026-10-26 (estimated)
Updated on ClinicalTrials.gov 2026-04-06